Clinical Trial Update: Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition [Phase 2]

View source ↗

Summary

Phase 2 trial update on inhibiting 11β-hydroxysteroid dehydrogenase type 1 to treat iatrogenic Cushing's syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iatrogenic Cushing Disease

Snippet

Sponsor: University of Oxford | Conditions: Iatrogenic Cushing's Disease | Phase 2 | Status: COMPLETED